Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Consorcio Centro De Investigacion Biomedica En Red M P manages a company patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action currently active. This 1 pending office action is assigned to 1 distinct examiner, meaning the company's current biological claims are under the review of a single individual. This prosecution activity is located within 1 distinct art unit.
The busiest examiner identified is MIKNIS, ZACHARY J, who handles 1 busiest examiner pending office action. Because the total number of pending office actions is 1, MIKNIS, ZACHARY J is the sole USPTO official responsible for the current workload. This creates a direct line of interaction between the applicant and the examiner within the Biotechnology & Pharmaceuticals sector.
Practitioners should observe that with 1 distinct examiner and 1 distinct art unit, there is no opportunity to compare different examination styles within the current portfolio. The progress of the 1 pending office action will be subject to the specific interpretations and requirements of MIKNIS, ZACHARY J. This focused structure requires a response strategy that addresses the particular standards of the single art unit involved in the biotechnology field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIKNIS, ZACHARY J | 1 | 68.5% | +32.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029913 | New Combinations of Boron Compounds and Adjuvants for the Treatment of Pathophysiological Conditions and Cancer and for Muscle Regeneration | MIKNIS, ZACHARY J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029913 | New Combinations of Boron Compounds and Adjuvants for the Treatment of Pathophysiological Conditions and Cancer and for Muscle Regeneration | MIKNIS, ZACHARY J | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18029913 | New Combinations of Boron Compounds and Adjuvants for the Treatment of Pathophysiological Conditions and Cancer and for Muscle Regeneration | MIKNIS, ZACHARY J | 1658 | §102§112 | Non-Final OA | — | Pending | Apr 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialConsorcio Centro De Investigacion Biomedica En Red M P has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Zachary J Miknis has the most, with 1 of Consorcio Centro De Investigacion Biomedica En Red M P's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
